FDA fast-track approval of belzutifan is a milestone in rare cancer therapy

IF 40 1区医学 Q1 ENDOCRINOLOGY & METABOLISM

Nature Reviews Endocrinology Pub Date : 2025-09-11 DOI:10.1038/s41574-025-01183-z

Carlota Arenillas, Rodrigo A. Toledo

引用次数: 0

Abstract

FDA approval of the selective HIF2α inhibitor belzutifan for advanced phaeochromocytoma and paraganglioma (PPGL) is an important milestone in precision oncology. This achievement underscores the power of scientific collaboration in establishing HIF2α as a central driver of PPGL pathogenesis and offers hope for a historically underserved group of patients.

Abstract Image

查看原文本刊更多论文

FDA快速批准贝祖替芬是罕见癌症治疗的一个里程碑

FDA批准选择性HIF2α抑制剂belzutifan治疗晚期嗜铬细胞瘤和副神经节瘤（PPGL）是精准肿瘤学的一个重要里程碑。这一成就强调了科学合作在确定HIF2α作为PPGL发病机制的核心驱动因素方面的力量，并为历史上服务不足的患者群体提供了希望。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Endocrinology 医学-内分泌学与代谢

CiteScore

42.00

自引率

0.70%

发文量

158

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Endocrinology aspires to be the foremost platform for reviews and commentaries catering to the scientific communities it serves. The journal aims to publish articles characterized by authority, accessibility, and clarity, enhanced with easily understandable figures, tables, and other visual aids. The goal is to offer an unparalleled service to authors, referees, and readers, striving to maximize the usefulness and impact of each article. Nature Reviews Endocrinology publishes Research Highlights, Comments, News & Views, Reviews, Consensus Statements, and Perspectives relevant to researchers and clinicians in the fields of endocrinology and metabolism. Its broad scope ensures that the work it publishes reaches the widest possible audience.